https://www.nasdaq.com/press-release/amneal-acquires-saol-therapeutics-baclofen-franchise-2022-01-05
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-the-40th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/amneal-receives-approval-for-difluprednate-ophthalmic-emulsion-2021-11-19
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-upcoming-investor-conferences-2021-11-12
https://www.nasdaq.com/press-release/amneal-reports-third-quarter-2021-financial-results-2021-11-03
https://www.nasdaq.com/press-release/amneal-releases-inaugural-corporate-responsibility-report-highlighting-our-impact-as
https://www.nasdaq.com/press-release/amneal-launches-generic-dexamethasone-following-anda-approval-by-fda-2021-10-27
https://www.nasdaq.com/press-release/amneal-to-report-third-quarter-2021-results-on-november-3-2021-2021-10-06
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-morgan-stanley-19th-annual-global-healthcare
https://www.nasdaq.com/press-release/amneal-announces-positive-topline-results-from-pivotal-phase-3-rise-pd-clinical-trial
https://www.nasdaq.com/press-release/amneal-announces-virtual-event-to-discuss-initial-data-from-pivotal-phase-3-study-of
https://www.nasdaq.com/press-release/amneal-reports-second-quarter-2021-financial-results-2021-08-09
https://www.nasdaq.com/press-release/amneal-receives-approval-for-generic-tobradexr-2021-07-19
https://www.nasdaq.com/press-release/amneal-to-report-second-quarter-2021-results-on-august-9-2021-2021-07-15
https://www.nasdaq.com/press-release/amneal-announces-u.s.-fda-filing-acceptance-of-biologics-license-application-bla-for
https://www.nasdaq.com/press-release/amneal-announces-dihydroergotamine-dhe-autoinjector-nda-for-migraines-and-cluster
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-upcoming-investor-conferences-2021-05-14
https://www.nasdaq.com/press-release/amneal-reports-first-quarter-2021-financial-results-2021-05-07
https://www.nasdaq.com/press-release/amneal-to-report-first-quarter-2021-results-on-may-7-2021-2021-04-15
https://www.nasdaq.com/press-release/amneal-completes-acquisition-of-kashiv-specialty-pharmaceuticals-2021-04-05
https://www.nasdaq.com/press-release/amneal-receives-approval-for-generic-version-of-ortho-evrar-2021-02-26
https://www.nasdaq.com/press-release/amneal-reports-fourth-quarter-and-full-year-2020-financial-results-2021-02-26
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-upcoming-investor-conferences-2021-02-22
https://www.nasdaq.com/press-release/amneal-to-report-fourth-quarter-full-year-2020-results-on-february-26-2021-2021-02-04
https://www.nasdaq.com/press-release/amneal-to-acquire-substantially-all-of-kashiv-specialty-pharmaceuticals-2021-01-12
https://www.nasdaq.com/press-release/amneal-launches-generic-abiraterone-acetate-tablets-usp-500-mg-following-anda
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-the-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/amneal-receives-abbreviated-new-drug-application-approval-for-acyclovir-cream-5-2020
https://www.nasdaq.com/press-release/amneal-reports-third-quarter-2020-financial-results-2020-11-06
https://www.nasdaq.com/press-release/amneal-to-report-third-quarter-2020-results-on-november-6-2020-2020-10-15
https://www.nasdaq.com/press-release/company-profile-for-amneal-pharmaceuticals-2020-10-08
https://www.nasdaq.com/press-release/amneal-pl-developments-launch-store-brand-program-of-over-the-counter-otc-diclofenac
https://www.nasdaq.com/press-release/amneal-to-virtually-participate-at-the-morgan-stanley-global-healthcare-conference
https://www.nasdaq.com/press-release/amneal-receives-abbreviated-new-drug-application-approval-for-lidocaine-patch-5-2020
https://www.nasdaq.com/press-release/amneal-reports-second-quarter-2020-financial-results-2020-08-06
https://www.nasdaq.com/press-release/amneal-launches-generic-fluphenazine-following-anda-approval-by-fda-2020-07-10
https://www.nasdaq.com/press-release/amneal-to-report-second-quarter-2020-results-on-august-6-2020-2020-07-08
https://www.nasdaq.com/press-release/amneal-reports-first-quarter-2020-financial-results-2020-05-11
https://www.nasdaq.com/press-release/amneal-to-report-first-quarter-2020-results-on-may-11-2020-2020-04-24
https://www.nasdaq.com/press-release/amneal-launches-generic-butransr-following-anda-approval-by-fda-2020-04-16
https://www.nasdaq.com/press-release/amneal-pharmaceuticals-moving-to-a-virtual-meeting-format-for-2020-annual-meeting-of
https://www.nasdaq.com/press-release/state-of-texas-and-senator-bryan-hughes-secure-a-donation-of-hydroxychloroquine
https://www.nasdaq.com/press-release/amneal-accelerates-distribution-and-production-of-hydroxychloroquine-sulfate-to-meet
https://www.nasdaq.com/press-release/amneal-pharmaceuticals-appoints-tasos-konidaris-as-senior-vice-president-chief
https://www.nasdaq.com/press-release/amneal-reports-fourth-quarter-and-full-year-2019-financial-results-2020-02-26
https://www.nasdaq.com/press-release/amneal-to-report-fourth-quarter-and-full-year-2019-results-on-february-26-2020-2020
https://www.nasdaq.com/press-release/amneal-pharmaceuticals-to-present-at-the-38th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/amneal-appoints-jeff-george-john-kiely-and-shlomo-yanai-to-board-of-directors-2019-12
https://www.nasdaq.com/press-release/amneal-receives-abbreviated-new-drug-application-approval-for-eluryngtm-the-first
https://www.nasdaq.com/press-release/amneal-to-acquire-majority-interest-in-avkare-enhancing-access-to-growing-federal
https://www.nasdaq.com/press-release/amneal-announces-the-approval-and-launch-of-generic-carafater-2019-12-03
https://www.nasdaq.com/press-release/amneal-announces-the-approval-and-launch-of-generic-revatior-for-oral-suspension-and
https://www.nasdaq.com/press-release/amneal-pharmaceuticals-to-present-at-the-piper-jaffray-31st-annual-healthcare
https://www.nasdaq.com/press-release/amneal-reports-third-quarter-2019-financial-results-2019-11-07
https://www.nasdaq.com/press-release/amneal-enters-into-a-licensing-agreement-with-kashiv-biosciences-llc-to-develop-and
https://www.nasdaq.com/press-release/nyse-welcomes-2019-global-leader-listings-2019-04-11-0
